[1] X. EMONDS-ALT . SR 142801, The first potent non-peptide antagonist of the tachykinin NK3 receptor[J]. Life sciences, 1994, 56 1: Pages PL27-PL32. DOI:
10.1016/0024-3205(94)00413-m[2] GUY GRIEBEL Sandra B. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases[J]. Pharmacology & Therapeutics, 2012, 133 1: Pages 116-123. DOI:
10.1016/j.pharmthera.2011.09.007[3] SOAZIG NÉNAN . Inhibition of inflammatory cell recruitment by the tachykinin NK3-receptor antagonist, SR 142801, in a murine model of asthma[J]. European journal of pharmacology, 2001, 421 3: Pages 201-205. DOI:
10.1016/s0014-2999(01)01036-6[4] N. SALOMÉ. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils[J]. Pharmacology Biochemistry and Behavior, 2006, 83 4: Pages 533-539. DOI:
10.1016/j.pbb.2006.03.013